# Polyrizon Ltd. (PLRZ)

> Source: Nexqual · https://nexqual.com/PLRZ · data as of 2026-10-23 20:00 UTC · cite as "Nexqual, Polyrizon Ltd. (PLRZ), nexqual.com/PLRZ" · informational, not investment advice.

**Price:** USD 8.73 (+0.05% on the day) · last close of Oct 23, 2026; US market closed, not a live price. Prev close 8.72 · day 8.73–9.37 · 52w 2.88–18.2 · market cap $21.2M · NCM

## Key facts
- Analysts: None.
- Total return with dividends: 1Y +35.9% vs S&P 500 +13.4%; 5Y -99.5% vs S&P 500 +76.9%.

## Analysts
Consensus None.

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-24) | 5Y (from 2024-10-28) |
|---|---|---|
| Total return | +35.9% | -99.5% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | +36.0% | -93.1% |
| Volatility (annualized) | 156.4% | 341.8% |
| Max drawdown | -52.1% (Oct 2025→Nov 2025) | -99.9% (Dec 2024→Nov 2025) |

## Peers (Biotechnology)
LGND (Ligand Pharmaceuticals Incorpor) USD 303.53 -1.39% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 89.27 -1.79% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.09 -0.35% · PRAX (Praxis Precision Medicines, Inc) USD 252.96 -2.30% · IONS (Ionis Pharmaceuticals, Inc.) USD 42.93 -2.23% · AXSM (Axsome Therapeutics, Inc.) USD 145.04 -7.07%

## More
Full page: https://nexqual.com/PLRZ · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in PLRZ's own 20-F filed 2026-03-25 (https://www.sec.gov/Archives/edgar/data/1893645/000121390026034198/ea0282602-20f_polyrizon.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | SciSparc Ltd. (SPRC) | "August 13, 2024, we entered into an exclusive patent license agreement, or the SciSparc License Agreement, with SciSparc Ltd., or SciSparc," |
| Partner | NV Gold Corp (NVGLF) | "On October 24, 2025, we entered into a subscription agreement with Taurus" |
| Partner | PharmaSeed | "The studies have been conducted mainly by our service partner PharmaSeed Ltd., Israel's" |
| Partner | Clearmind Medicine Inc. (CMND) | "Company has entered into a development agreement with Clearmind Medicine Inc. (Nasdaq: CMND) ("Clearmind"), a clinical stage" |
| Partner | Medigus | "February 4, 2023, we entered into a convertible loan agreement with Medigus Ltd. (which subsequently changed its name to Xylo Technologies" |
| Partner | Xylo Technologies | "February 4, 2023, we entered into a convertible loan agreement with Medigus Ltd. (which subsequently changed its name to Xylo Technologies" |
| Partner | Reuven Srugo Construction Company | "February 4, 2023, we entered into a convertible loan agreement with Reuven Srugo Construction Company Ltd., or Reuven Construction, pursuant" |
| Partner | QUANTUM X LABS INC. (QXL) | "December 15, 2025, Viewbix entered into a securities exchange agreement with Quantum X Labs Ltd. or Quantum, pursuant to which Viewbix" |

Other companies that name PLRZ in their own reports (relationship from PLRZ's side):

| Relationship | Company | Their filing | Sentence |
|---|---|---|---|
| partner | SciSparc Ltd. (SPRC) | 20-F 2026-04-29 | "In addition, in August 2024, we entered into an exclusive patent license agreement with Polyrizon Ltd.," |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |